We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Clarifies Endpoints for Adult, Pediatric Acute Heart Failure Trials
EMA Clarifies Endpoints for Adult, Pediatric Acute Heart Failure Trials
The European Medicines Agency last month released final guidance on the primary and secondary endpoints sponsors should use to evaluate drugs to treat acute heart failure — along with recommendations on designing and conducting such studies in children.